Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector

P. S. Becker, Jason Taylor, G. D. Trobridge, X. Zhao, B. C. Beard, S. Chien, J. Adair, D. B. Kohn, J. E. Wagner, A. Shimamura, H. P. Kiem

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34+cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5%) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21% oxygen without NAC (P

Original languageEnglish (US)
Pages (from-to)1244-1252
Number of pages9
JournalGene Therapy
Volume17
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Fanconi Anemia
Bone Marrow Cells
Safety
Acetylcysteine
Transcriptional Regulatory Elements
Marmota
Oxygen
Phosphoglycerate Kinase
Thrombopoietin
Lentivirus
Methylcellulose
Stem Cell Factor
Reducing Agents
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cells
Fibronectins
Genetic Therapy
DNA Damage
Free Radicals
Intercellular Signaling Peptides and Proteins

Keywords

  • gene therapy
  • Hhypoxia
  • mitomycin C
  • reducing agent

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. / Becker, P. S.; Taylor, Jason; Trobridge, G. D.; Zhao, X.; Beard, B. C.; Chien, S.; Adair, J.; Kohn, D. B.; Wagner, J. E.; Shimamura, A.; Kiem, H. P.

In: Gene Therapy, Vol. 17, No. 10, 10.2010, p. 1244-1252.

Research output: Contribution to journalArticle

Becker, PS, Taylor, J, Trobridge, GD, Zhao, X, Beard, BC, Chien, S, Adair, J, Kohn, DB, Wagner, JE, Shimamura, A & Kiem, HP 2010, 'Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector', Gene Therapy, vol. 17, no. 10, pp. 1244-1252. https://doi.org/10.1038/gt.2010.62
Becker, P. S. ; Taylor, Jason ; Trobridge, G. D. ; Zhao, X. ; Beard, B. C. ; Chien, S. ; Adair, J. ; Kohn, D. B. ; Wagner, J. E. ; Shimamura, A. ; Kiem, H. P. / Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. In: Gene Therapy. 2010 ; Vol. 17, No. 10. pp. 1244-1252.
@article{7645be0d34204b76a21d22ac78d52493,
title = "Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector",
abstract = "One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34+cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5{\%}) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21{\%} oxygen without NAC (P",
keywords = "gene therapy, Hhypoxia, mitomycin C, reducing agent",
author = "Becker, {P. S.} and Jason Taylor and Trobridge, {G. D.} and X. Zhao and Beard, {B. C.} and S. Chien and J. Adair and Kohn, {D. B.} and Wagner, {J. E.} and A. Shimamura and Kiem, {H. P.}",
year = "2010",
month = "10",
doi = "10.1038/gt.2010.62",
language = "English (US)",
volume = "17",
pages = "1244--1252",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector

AU - Becker, P. S.

AU - Taylor, Jason

AU - Trobridge, G. D.

AU - Zhao, X.

AU - Beard, B. C.

AU - Chien, S.

AU - Adair, J.

AU - Kohn, D. B.

AU - Wagner, J. E.

AU - Shimamura, A.

AU - Kiem, H. P.

PY - 2010/10

Y1 - 2010/10

N2 - One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34+cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5%) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21% oxygen without NAC (P

AB - One of the major hurdles for the development of gene therapy for Fanconi anemia (FA) is the increased sensitivity of FA stem cells to free radical-induced DNA damage during ex vivo culture and manipulation. To minimize this damage, we have developed a brief transduction procedure for lentivirus vector-mediated transduction of hematopoietic progenitor cells from patients with Fanconi anemia complementation group A (FANCA). The lentiviral vector FancA-sW contains the phosphoglycerate kinase promoter, the FANCA cDNA, and a synthetic, safety-modified woodchuck post transcriptional regulatory element (sW). Bone marrow mononuclear cells or purified CD34+cells from patients with FANCA were transduced in an overnight culture on recombinant fibronectin peptide CH-296, in low (5%) oxygen, with the reducing agent, N-acetyl-L-cysteine (NAC), and a combination of growth factors, granulocyte colony-stimulating factor (G-CSF), Flt3 ligand, stem cell factor, and thrombopoietin. Transduced cells plated in methylcellulose in hypoxia with NAC showed increased colony formation compared with 21% oxygen without NAC (P

KW - gene therapy

KW - Hhypoxia

KW - mitomycin C

KW - reducing agent

UR - http://www.scopus.com/inward/record.url?scp=77957988687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957988687&partnerID=8YFLogxK

U2 - 10.1038/gt.2010.62

DO - 10.1038/gt.2010.62

M3 - Article

C2 - 20485382

AN - SCOPUS:77957988687

VL - 17

SP - 1244

EP - 1252

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 10

ER -